EAST WINDSOR, N.J.--(BUSINESS WIRE)--NexMed, Inc. (Nasdaq: NEXM), a developer of innovative transdermal products based on its proprietary NexACT® drug delivery technology, today announced that Health Canada has accepted the New Drug Submission (NDS) for its topical erectile dysfunction (ED) treatment for review. Health Canada’s target is to complete review within three hundred (300) days for ninety percent (90%) of submissions.
